Symantec acquires Luminate in an effort to peruse cloud security
Category: #headlines  By Pankaj Singh  Date: 2019-02-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Symantec acquires Luminate in an effort to peruse cloud security

Luminate’s ‘Secure Access Cloud™ ‘ further extends Symantec’s ‘Integrated Cyber Defense Platform’ expertise to users.

Renowned California-based software magnate Symantec Corp has made it to the headlines for having apparently put forth an acquisition offer for Luminate Security. As per credible reports, the cybersecurity firm planned the takeover of the Israel-based company in a bid to accelerate its security systems for cloud computing.

Trusted sources with the knowledge of the matter claim that Luminate Security's Secure Access Cloud tech will now extend the capability of Symantec’s Integrated Cyber Defense Platform to users without them having to consider the infrastructure through which they are accessed or where they deploy their workloads. Ergo, the buyout will help Symantec offer highly secure, enhanced cloud-based services to its customers, the sources add.

The acquisition of Luminate marks Symantec’s third Israeli company takeover in the last couple of years. A global leader in the domain of information security, Symantec, also one of the biggest anti-virus software suppliers across the globe, acquired Israeli firms Fireglass, specializing in browser isolation, for around USD 250 million and SkyCure, specializing in mobile device protection, also for USD 250 million, in 2017.

For the uninitiated, Luminate’s cyber security technology is built for today's cloud-driven world and enables enterprises to scale ‘no DNS’ access control and provide user connections only to specific applications and resources.

According to an official press release by Symantec, Greg Clark, President and CEO of the company, was quoted stating that in an era where more and more corporations are liable to now run their business on infrastructure operated by third parties like AWS, Google, and Azure, retaining trust in external infrastructure remains a crucial consideration. Amid this scenario, incorporating Luminate in the company’s Integrated Cyber Defense Platform puts Symantec at the forefront of cloud security, Clark affirms.

Further elaborating on the acquisition, Clark added that Symantec is thrilled to join hands with Luminate and looks forward to the robust delivery of this capability to its customers and continue providing significant value to users’ cloud journey.

As per reliable sources neither Symantec Corp nor Luminate Security have disclosed any financial details pertaining to the said acquisition so far.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Merck acquires Calporta Therapeutics from COI Pharmaceuticals
Merck acquires Calporta Therapeutics from COI Pharmaceuticals
By Pankaj Singh

Merck will pay up to $576 million for the acquisition   Preclinical TRPML1 has the potential to treat neurodegenerative and lysosomal disorders COI Pharmaceuticals has recently announced that Merck, also called MSD outside Canada and the U...

Personalis unveils new service for cancer whole genome sequencing
Personalis unveils new service for cancer whole genome sequencing
By Pankaj Singh

  The new launch of the services will help the company expand its oncology portfolio Personalis has been able to sequence more than 40,000 MVP samples since 2013. Personalis, Inc., a leading advanced genomics firm for cancer, recently unve...

Celltrion depicts CT-P13 SC efficacy for treating rheumatoid arthritis
Celltrion depicts CT-P13 SC efficacy for treating rheumatoid arthritis
By Pankaj Singh

Celltrion Healthcare, a biopharmaceutical company, recently announced data from a study further investigating efficacy, safety, immunogenicity & pharmacokinetics of CT-P13 SC, over a period of 1-year treatment. The study focuses on the results ac...